Based on the provided insights, there are no current investment recommendations or actionable opportunities for Johnson & Johnson (JNJ). Historical medical products like snake bite kits highlight how quickly outdated health practices can become obsolete as medical science advances. Investors should always evaluate a pharmaceutical company's current R&D pipeline rather than rely on legacy product history. Stay tuned for future updates when specific price targets or high-conviction trades become available for this sector.

Pharmaceuticals / Biotech (Johnson & Johnson - JNJ)

• Mentioned in the context of historical medical products, specifically noting that Johnson & Johnson used to sell rattlesnake bite kits that recommended slicing the wound, applying a tourniquet, and attempting to suck out the venom.
• The guests discussed how these historical kits are now known to be completely ineffective and medically unsound for treating venomous snake bites.

Takeaways

• Historical medical practices and over-the-counter health kits can become obsolete or dangerous as medical science advances.
• No specific investment recommendation or price target was mentioned in the transcript regarding Johnson & Johnson stock.